65.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.04
Aprire:
$65.71
Volume 24 ore:
3.74M
Relative Volume:
1.92
Capitalizzazione di mercato:
$12.59B
Reddito:
$4.41B
Utile/perdita netta:
$21.27M
Rapporto P/E:
203.31
EPS:
0.32
Flusso di cassa netto:
$288.81M
1 W Prestazione:
+1.27%
1M Prestazione:
+7.66%
6M Prestazione:
-12.78%
1 anno Prestazione:
+13.54%
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
65.06 | 12.44B | 4.41B | 21.27M | 288.81M | 0.32 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-12-17 | Iniziato | UBS | Neutral |
2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-10-01 | Iniziato | Wolfe Research | Outperform |
2024-09-18 | Downgrade | Truist | Buy → Hold |
2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
2024-05-23 | Iniziato | Deutsche Bank | Hold |
2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
2024-02-23 | Iniziato | Jefferies | Buy |
2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-11-21 | Downgrade | Goldman | Buy → Neutral |
2023-07-25 | Iniziato | Citigroup | Buy |
2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
2023-01-31 | Iniziato | Piper Sandler | Overweight |
2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2021-01-07 | Iniziato | Truist | Buy |
2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-06-16 | Iniziato | The Benchmark Company | Hold |
2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-03-24 | Ripresa | William Blair | Outperform |
2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2020-02-04 | Ripresa | BofA/Merrill | Neutral |
2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
2019-10-03 | Iniziato | Mizuho | Buy |
2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
2019-05-21 | Iniziato | Credit Suisse | Neutral |
2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
2019-04-11 | Iniziato | Stifel | Hold |
2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? - Yahoo Finance
Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance
Incyte (NASDAQ:INCY) Price Target Raised to $73.00 at Truist Financial - Defense World
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India
Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus
Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus
Incyte to Present at Upcoming Investor Conference - Business Wire
Incyte Co. (NASDAQ:INCY) Shares Bought by Cetera Investment Advisers - Defense World
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance
Is Wall Street Bullish or Bearish on Incyte Stock? - inkl
Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com
Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN
Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus
Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace
No Article III Appellate Standing Under the Sun - Lexology
FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (I - GuruFocus
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus
FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com
Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus
Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Incyte settles royalty dispute with Novartis for $280 million - Investing.com
Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com
Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma
Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com
Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):